CFM
ORMP icon

Catalyst Funds Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Catalyst Funds Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,500
Closed -$79.9K – 828
2026
Q1 		$79.9K Buy
+23,500
New +$79.7K 0.01% 508

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Catalyst Funds Management's ORMP Position: Q2 2026 in Review

Catalyst Funds Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2026, closing a stake of 23,500 shares — an estimated $79.9K sold.

Catalyst Funds Management first reported a position in ORMP in Q1 2026 and held it in 1 quarter. The position peaked at $79.9K in Q1 2026. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Catalyst Funds Management reported no remaining Oramed Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 23,500 Oramed Pharmaceuticals shares in Q2 2026, an estimated $79.9K.
  • Catalyst Funds Management first reported a position in Oramed Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Catalyst Funds Management's Oramed Pharmaceuticals position peaked at $79.9K in Q1 2026.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.